GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Galera Therapeutics
Gryphon Digital Mining is a Bitcoin mining company focused on green energy. Its stock price directly tracks the Bitcoin price. The chart reflects crypto market volatility and investor sentiment toward greener mining.
Share prices of companies in the market segment - Oncology platforms
Galera Therapeutics is a biopharmaceutical company developing drugs to protect healthy tissue from the side effects of radiation therapy in cancer treatment. We've classified it as an "Oncology Platform." The chart below shows how the market values companies improving oncology therapy.
Broad Market Index - GURU.Markets
Galera Therapeutics is an oncology company developing drugs to protect healthy tissue from the side effects of radiation therapy. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Galera shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
GRTX - Daily change in the company's share price Galera Therapeutics
Galera Therapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drugs to reduce the side effects of radiation therapy.
Daily change in the price of a set of shares in a market segment - Oncology platforms
Galera Therapeutics developed drugs to protect healthy tissue from the side effects of radiation therapy. The company experienced clinical trial failures, which is typical for the biotech sector. The chart below shows the volatility of this industry, illustrating the high risks faced by companies like GRTX.
Daily change in the price of a broad market stock, index - GURU.Markets
Galera Therapeutics is a biotech company developing drugs to reduce the side effects of radiation therapy. Its shares are driven by news of clinical trials. This high volatility, driven by innovation, is a significant contributor to the overall "noise" and dynamics of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Galera Therapeutics
For Galera Therapeutics, year-over-year performance is the story of its fight for drug approval. Its 12-month market cap is fundamentally dependent on FDA decisions. The denial of approval for its drug for the treatment of radiation therapy side effects was a major blow, and its valuation now reflects its belief in its ability to appeal the decision.
Annual dynamics of market capitalization of the market segment - Oncology platforms
Galera, a late-stage biotech company, develops drugs to reduce the side effects of radiation therapy. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs in this field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Galera Therapeutics, a biotech company plagued by research setbacks, tells the story of its struggle for survival. Its performance, compared to the market, reflects investors' confidence in the remaining drugs in its portfolio. It's a risky bet on the company's ability to recover.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Galera Therapeutics
Galera is a biopharmaceutical company focused on the side effects of radiation therapy. Its monthly performance is entirely dependent on the results of its clinical trials and interactions with the FDA. Regulatory news is the main driver of its value.
Monthly dynamics of market capitalization of the market segment - Oncology platforms
Galera Therapeutics develops drugs to protect healthy tissue from the side effects of radiation therapy. This is an important supportive therapy in oncology. The dynamics of the biotech sector underscore the overall context in which Galera is trying to prove that its product can significantly improve the quality of life for cancer patients, becoming a new standard of care.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs to protect healthy tissue from the side effects of radiation therapy. The company's future depends on the success of its clinical trials. The broader market chart serves as a backdrop to understand how its potential to improve the quality of life for cancer patients has impacted its stock price.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Galera Therapeutics
Galera Therapeutics is a clinical-stage biopharmaceutical company developing drugs to protect healthy tissue from the side effects of radiation therapy. Its weekly stock price is driven by news about clinical trials and regulatory decisions.
Weekly dynamics of market capitalization of the market segment - Oncology platforms
Galera Therapeutics develops drugs to protect healthy tissue during radiation therapy. This is an important supportive therapy in oncology. The chart will help you understand whether Galera's share price performance is related to its own clinical results or a general reaction to news in the supportive care sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Galera is a biotech company whose stock moves on news about clinical trials. This chart clearly demonstrates how much its performance is driven by scientific news rather than general market trends.
Market capitalization of the company, segment and market as a whole
GRTX - Market capitalization of the company Galera Therapeutics
Galera Therapeutics' market capitalization chart is a tale of biotech disappointment. Its sharp decline reflects the regulator's denial of approval for its lead drug. The current low valuation reflects investor skepticism about the company's future, despite its efforts to secure approval.
GRTX - Share of the company's market capitalization Galera Therapeutics within the market segment - Oncology platforms
Galera Therapeutics is a biotech company specializing in drugs to reduce the side effects of radiation therapy. Its market share in the oncology sector is small, but it is targeting an important supporting niche. Its market capitalization reflects its research progress and market confidence in the commercial potential of its developments.
Market capitalization of the market segment - Oncology platforms
Here's a chart showing the biotech sector's market capitalization. Galera Therapeutics specializes in drugs that protect healthy tissue from radiation therapy. This market has enormous potential, as it could significantly improve the quality of life for cancer patients. Galera's story is rooted in the search for a solution to this important medical problem.
Market capitalization of all companies included in a broad market index - GURU.Markets
Galera Therapeutics develops drugs to protect healthy tissue from the side effects of radiation therapy. Its market capitalization is based on the hope of improving the quality of life for cancer patients. The graph below shows the economic weight of the oncology supportive care sector.
Book value capitalization of the company, segment and market as a whole
GRTX - Book value capitalization of the company Galera Therapeutics
Galera Therapeutics' foundation is its intellectual property for drugs designed to reduce the toxicity of radiation therapy. The chart tells the complex story of a biotech company that faced regulatory rejection and is now using its remaining capital to conduct new research in hopes of proving the effectiveness of its technology.
GRTX - Share of the company's book capitalization Galera Therapeutics within the market segment - Oncology platforms
Galera Therapeutics develops drugs to protect against the side effects of radiation therapy. The chart shows its share of actual R&D assets. These include its laboratories and clinical programs, which provide the material basis for its developments.
Market segment balance sheet capitalization - Oncology platforms
Galera Therapeutics is a biopharmaceutical company developing drugs to reduce the toxicity of radiation therapy. Their value lies in their scientific developments. The book value chart reflects the value of their R&D base but does not convey the potential value of their intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Galera Therapeutics' assets include laboratories and R&D centers for developing drugs that protect healthy tissue from radiation therapy. The chart shows how the company built its scientific and material capital to address this important problem in oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Galera Therapeutics
Galera Therapeutics is developing drugs to reduce the side effects of radiation therapy. Its value lies in its intellectual property. The chart below is a typical biotech story of hopes and disappointments. The dynamics will depend entirely on the results of clinical trials, which will either create or destroy value.
Market to book capitalization ratio in a market segment - Oncology platforms
Galera Therapeutics develops drugs to reduce the serious side effects of radiation therapy in cancer patients. The company's valuation depends on the success of its clinical programs and regulatory approvals. The chart shows how its market capitalization, based on these expectations, compares to its current assets.
Market to book capitalization ratio for the market as a whole
Galera Therapeutics is a biotech company focused on reducing the side effects of radiation therapy. Its value is entirely dependent on the success of clinical trials. This metric demonstrates that investors value the potential of its drugs to improve patients' quality of life, not its current physical assets.
Debts of the company, segment and market as a whole
GRTX - Company debts Galera Therapeutics
Galera Therapeutics is a biotech company that has experienced setbacks in clinical trials of its drugs to reduce the side effects of radiation therapy. This graph reflects its financial difficulties. The company has been forced to drastically reduce its workforce and is seeking strategic alternatives to survive.
Market segment debts - Oncology platforms
Galera Therapeutics developed drugs to reduce the side effects of radiation therapy. After failing a key clinical trial, the company faced serious difficulties. This chart illustrates how the binary outcome of clinical trials affects the financial fate of a biotech company.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Galera Therapeutics
Galera Therapeutics is a clinical-stage biopharmaceutical company. This chart shows its financial structure. For a company whose developments have not yet been approved, debt is a significant burden. Failure in trials could make it impossible to maintain and threaten the company's survival.
Market segment debt to market segment book capitalization - Oncology platforms
Galera Therapeutics is a biopharmaceutical company developing drugs to protect healthy tissue from the side effects of radiation therapy. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its clinical trials and the launch of maintenance drugs.
Debt to book value of all companies in the market
Galera Therapeutics is a biopharmaceutical company developing drugs to reduce the side effects of radiation therapy. Improving patients' quality of life is an important niche. This chart of total market debt helps understand the company's funding environment for the commercialization of its specialized products.
P/E of the company, segment and market as a whole
P/E - Galera Therapeutics
Galera Therapeutics is a biotech company focused on developing drugs to protect healthy tissue from the side effects of cancer radiation therapy. This chart reflects investor disappointment after clinical trial failures. Its dynamics highlight how risky biotech investments can be.
P/E of the market segment - Oncology platforms
Galera Therapeutics is a biopharmaceutical company developing drugs to protect healthy tissue from the toxicity of radiation therapy in cancer patients. Their goal is to improve patients' quality of life. This chart shows the average valuation for the oncology sector, reflecting how investors value drugs aimed at reducing treatment side effects.
P/E of the market as a whole
Galera Therapeutics is a biopharmaceutical company developing drugs to protect healthy tissue from the side effects of radiation therapy. Its valuation depends entirely on the success of its drugs in clinical trials. The overall market sentiment reflected in this chart is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Galera Therapeutics
Galera Therapeutics is a biopharmaceutical company developing drugs to protect healthy tissue from the side effects of cancer radiation therapy. This chart shows market expectations for the success of its lead candidate. Future revenue is entirely dependent on regulatory approval and clinical implementation.
%20P%2FE%20Galera%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Galera-Therapeutics&v=1772669089853 "Chart of the company's future (projected) P/E Galera Therapeutics")
Future (projected) P/E of the market segment - Oncology platforms
Galera Therapeutics develops drugs to reduce the toxicity of radiation therapy in cancer patients. The chart reflects average profitability expectations for the biotech sector. GRTX's position relative to this benchmark reflects the market's assessment of their chances of success in clinical trials and their potential to become a standard of care for patients undergoing radiation therapy.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-platforms&v=1772669089863 "Future (projected) P/E graph of the market segment - Oncology platforms")
Future (projected) P/E of the market as a whole
Galera Therapeutics is a biopharmaceutical company developing drugs to protect healthy tissue from the side effects of radiation therapy during cancer treatment. Its goal is to improve the quality of life of cancer patients. This chart of general market expectations provides a backdrop for evaluating companies operating in the marginal yet important oncology care market.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772669089880 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Galera Therapeutics
Galera Therapeutics is a biotechnology company developing drugs to protect healthy tissue from the side effects of cancer radiation therapy. Its financial schedule reflects clinical trial costs. Future profitability depends on FDA approval and the successful implementation of its drugs in oncology practice.
Profit of companies in the market segment - Oncology platforms
Galera Therapeutics develops drugs to protect healthy tissue from the side effects of radiation therapy. This is an important area of supportive care in oncology. This chart shows the overall profitability of the oncology platform sector. It reflects investment interest and scientific progress in developing drugs that improve the quality of life for cancer patients.
Overall market profit
Galera Therapeutics develops drugs to protect healthy tissue from the side effects of radiation therapy. This is an important niche in oncology. The company's success depends on clinical data and regulatory approval. The overall market situation, reflected in this chart, impacts its ability to raise capital to complete research and bring the product to market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Galera Therapeutics
Galera Therapeutics develops drugs to protect healthy tissue from the side effects of radiation therapy during cancer treatment. This chart reflects analysts' expectations for the commercial potential of its lead candidate, which could significantly improve the quality of life for cancer patients.
%20profit%20of%20the%20company%20Galera%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Galera-Therapeutics&v=1772669089962 "Graph of future (projected) profit of the company Galera Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology platforms
Galera Therapeutics develops drugs to protect healthy tissue from the side effects of radiation therapy during cancer treatment. The company's success depends on the results of clinical trials and the need to improve the quality of life of cancer patients. This chart reflects forecasts for the entire biotech sector, helping to assess Galera's potential in the important niche of supportive care.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-platforms&v=1772669089971 "Graph of future (predicted) profits of companies in a market segment - Oncology platforms")
Future (predicted) profit of the market as a whole
Galera Therapeutics is a biopharmaceutical company developing drugs to reduce the side effects of radiation therapy. Its success depends on clinical trial results and regulatory approval. The macroeconomic indicators shown in this chart are not relevant for assessing its potential.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772669089997 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Galera Therapeutics
Galera Therapeutics is a biopharmaceutical company focused on protecting healthy tissue from the side effects of cancer radiation therapy. This chart shows how investors view the potential of its drugs. The trend reflects clinical trial results and the belief that its products will become the standard of care for cancer patients.
P/S market segment - Oncology platforms
Galera Therapeutics develops drugs to protect healthy tissue from the side effects of cancer radiation therapy. Future revenue depends on the success of these developments. This oncology sector chart helps assess how investors view the potential of Galera's drugs to improve the quality of life for cancer patients and become a standard of care.
P/S of the market as a whole
Galera Therapeutics is a biotech company developing drugs to protect healthy tissue from the side effects of radiation therapy for cancer. This market revenue valuation chart helps understand how investors view the company's potential to improve the quality of life for cancer patients.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Galera Therapeutics
Galera Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs to protect healthy tissue from the side effects of cancer radiation therapy. This chart shows how the market perceives the future commercial potential of its lead candidate. It reflects investor expectations for its approval and clinical implementation.
%20P%2FS%20Galera%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Galera-Therapeutics&v=1772669090057 "The graph of the company's future (projected) P/S Galera Therapeutics")
Future (projected) P/S of the market segment - Oncology platforms
Galera Therapeutics is a biopharmaceutical company focused on developing drugs to reduce the toxicity of radiation therapy in cancer patients. The company's valuation reflects the company's hope that its lead candidate will significantly improve the quality of life of patients undergoing cancer treatment, a significant unmet need.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-platforms&v=1772669090062 "Future (projected) P/S market segment graph - Oncology platforms")
Future (projected) P/S of the market as a whole
Galera Therapeutics develops drugs to protect healthy tissue during radiation therapy. The company aims to improve the quality of life of cancer patients. In the overall revenue growth picture illustrated by the chart, Galera represents an important segment of the maintenance therapy market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772669090070 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Galera Therapeutics
Galera Therapeutics is a biotech company focused on developing drugs to reduce the toxicity of radiation therapy. Its lead candidate is designed to reduce severe oral mucositis in cancer patients. While the company is in the approval stage, it does not yet have any revenue.
Sales of companies in the market segment - Oncology platforms
Galera Therapeutics (GRTX) develops drugs to protect healthy tissue from the side effects of radiation therapy and enhance its effectiveness in cancer treatment. This figure reflects revenue in the oncology sector. Galera's products can significantly improve the quality of life of cancer patients by reducing the toxicity of standard treatments.
Overall market sales
Galera Therapeutics develops drugs to protect healthy tissue from the side effects of radiation therapy. Its success depends on clinical data and the acceptance of its products by physicians. This overall economic activity affects healthcare system budgets and its willingness to implement new maintenance therapy drugs that can improve patients' quality of life.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Galera Therapeutics
Galera Therapeutics is a biotech company developing drugs to protect healthy tissue from the side effects of cancer radiation therapy. Future revenue depends on the approval and commercialization of its lead drug. This chart reflects analyst sales forecasts, which estimate potential demand for therapies that improve the quality of life for cancer patients.
%20sales%20of%20the%20company%20Galera%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Galera-Therapeutics&v=1772669090085 "Schedule of future (projected) sales of the company Galera Therapeutics")
Future (projected) sales of companies in the market segment - Oncology platforms
Galera Therapeutics develops drugs to protect healthy tissue from the side effects of radiation therapy. This graph shows the potential future revenue of their lead candidate. This is analysts' view of the commercial prospects for this drug, which has the potential to significantly improve the quality of life for cancer patients.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-platforms&v=1772669090086 "Schedule of future (projected) sales of companies in the market segment - Oncology platforms")
Future (projected) sales of the market as a whole
Galera Therapeutics develops drugs to protect healthy tissue from the side effects of radiation therapy. Its goal is to improve the quality of life of cancer patients. This graph illustrates general trends in healthcare, and Galera's success will depend on its ability to demonstrate that its drugs can significantly reduce the toxicity of standard cancer treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772669090090 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Galera Therapeutics
Galera Therapeutics is a biopharmaceutical company developing drugs to reduce the toxicity of radiation therapy in cancer patients. The company's profitability depends on the success of clinical trials and the acceptance of its drugs by doctors. The chart illustrates the company's financial trajectory as it strives to improve the quality of life for cancer patients.
Market segment marginality - Oncology platforms
Galera Therapeutics is a biopharmaceutical company focused on developing drugs to reduce the toxicity of radiation therapy in cancer patients. This chart reflects its operating expenses. The path to profitability depends on the approval of its drugs and their acceptance by oncologists as standard treatment.
Market marginality as a whole
Galera Therapeutics develops drugs to reduce the toxicity of radiation therapy in cancer patients. The company's success depends on the introduction of its products into clinical practice. This gross profitability chart reflects the financial health of hospitals. Their ability to procure new drugs for maintenance therapy determines Galera's commercial potential.
Employees in the company, segment and market as a whole
Number of employees in the company Galera Therapeutics
Galera Therapeutics develops drugs designed to protect healthy tissue from the side effects of radiation therapy during cancer treatment. This graphic shows the team working to make cancer treatment more gentle and improve the quality of life for patients going through this difficult ordeal.
Share of the company's employees Galera Therapeutics within the market segment - Oncology platforms
Galera Therapeutics is a biotech company focused on protecting healthy tissue from the side effects of radiation therapy. Its staff consists of a team of scientists and clinicians advancing its drugs through clinical trials. This chart shows the company's human resources dedicated to improving the quality of life for cancer patients.
Number of employees in the market segment - Oncology platforms
Galera Therapeutics develops drugs to protect healthy tissue from the side effects of radiation therapy. This chart, showing employment in oncology platforms, illustrates the company's search for ways to improve patients' quality of life. For Galera, growth in this area means increased demand for its drugs, which could make cancer treatment more tolerable.
Number of employees in the market as a whole
Galera Therapeutics is developing drugs to protect healthy tissue from the side effects of radiation therapy. The company's success depends on the integration of its products into standard cancer treatments. A strong economy, reflected by the employment growth in this chart, ensures stable funding for the healthcare system, allowing clinics to implement new methods to improve patients' quality of life.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Galera Therapeutics (GRTX)
Galera Therapeutics (GRTX) is a biotech company developing drugs to protect against the side effects of radiation therapy. As with any biotech company in the R&D stage, this chart shows the market valuation of their scientific platform. Their market capitalization is not dependent on the number of employees, but is determined solely by the potential of their developments.
%20of%20the%20company%20Galera%20Therapeutics%20(GRTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Galera-Therapeutics-GRTX&v=1772669090241 "Chart of market capitalization per employee (in thousands of dollars) of the company Galera Therapeutics (GRTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology platforms
Galera Therapeutics develops drugs to reduce the side effects of radiation therapy. This is an important niche in oncology. This chart shows how the market perceives the potential of its drugs to improve the quality of life of cancer patients, which translates into the high value of its scientific team.
%20by%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-platforms&v=1772669090248 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology platforms")
Market capitalization per employee (in thousands of dollars) for the overall market
Galera Therapeutics is a biopharmaceutical company developing drugs to protect healthy tissue from the side effects of radiation therapy. Its research is in the late stages. This chart for Galera shows how, in biotech, market capitalization per employee reflects the potential to solve an important medical problem that improves patients' quality of life.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772669090251 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Galera Therapeutics (GRTX)
Galera Therapeutics is another biotech R&D company focused on oncology. Like its peers in the sector, it is unprofitable. This chart shows expenses, not revenue: the loss (investment) per employee working on clinical trials and drug development.
%20Chart%20Galera%20Therapeutics%20(GRTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Galera-Therapeutics-GRTX&v=1772669090252 "Company Profit Per Employee (in thousands of dollars) Chart Galera Therapeutics (GRTX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology platforms
Galera Therapeutics develops drugs to protect healthy tissue during cancer radiation therapy. In supportive oncology therapy, the effectiveness of clinical trials determines speed to market. This metric demonstrates the value each employee creates by working to improve the quality of life for cancer patients.
%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-platforms&v=1772669090265 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology platforms")
Profit per employee (in thousands of dollars) for the market as a whole
Galera Therapeutics is a biotech company developing drugs to protect healthy tissue in patients undergoing radiation therapy for cancer. This chart, showing the market average profit per employee, provides important context. It illustrates the high stakes in biotech, where a single successful development can generate colossal profits per scientist.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772669090270 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Galera Therapeutics (GRTX)
Galera Therapeutics is a biopharmaceutical company developing drugs to reduce the toxicity of radiation therapy. Being in clinical trials, the company does not yet have significant commercial revenue. The graph shows minimal values, and its future growth depends on the successful approval of its drug candidates.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Galera-Therapeutics-GRTX&v=1772669090289 "Sales chart per company employee Galera Therapeutics (GRTX)")
Sales per employee in the market segment - Oncology platforms
Galera Therapeutics (GRTX) is a biopharmaceutical company specializing in developing drugs to protect healthy tissue from the side effects of cancer radiation therapy. This chart shows the average revenue per employee in the sector. It helps investors evaluate the company's capital efficiency during clinical development.
Sales per employee for the market as a whole
Galera Therapeutics (GRTX) is a biopharmaceutical company developing drugs to protect healthy tissue in patients undergoing radiation therapy. The company has experienced setbacks in R&D. This reflects the company's efforts to find a path to commercialization by using its scientific staff to analyze data and potentially conduct new research.
Short shares by company, segment and market as a whole
Shares shorted by company Galera Therapeutics (GRTX)
Galera Therapeutics (GRTX) is a biotech that failed a pivotal Phase III trial of its lead drug for treating radiation therapy side effects. This chart shows short interest. High bearish bets reflect investor expectations that the company has no valuable assets left and is headed for delisting or bankruptcy. (345)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Galera-Therapeutics-GRTX&v=1772669090330 "Short Shares Chart for the Company Galera Therapeutics (GRTX)")
Shares shorted by market segment - Oncology platforms
Galera Therapeutics (GRTX) develops drugs to protect healthy tissue in patients undergoing radiation therapy for cancer. The chart below shows the overall short position in the oncology biotech sector, reflecting the degree of investor skepticism about the commercial potential of maintenance therapy.
Shares shorted by the overall market
Galera Therapeutics is a clinical-stage biotech. When this chart shows rising fear, speculative, pre-profitable companies are the first to suffer. Investors aren't willing to wait years for FDA approval. They see GRTX as a money-burning pit and are selling off shares, fearing that in a risk-off environment, the company won't be able to attract new capital for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Galera Therapeutics (GRTX)
Galera Therapeutics is a biotech company focused on protecting patients from the side effects of radiation therapy. This is an important niche. This graph represents the "pulse" of FDA decisions. The "temperature" was "overheated" in anticipation of approval, but "cooled" (collapsed) after the FDA rejected the drug.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Galera-Therapeutics-GRTX&v=1772669090382 "RSI 14 indicator chart for the company's stock Galera Therapeutics (GRTX)")
RSI 14 Market Segment - Oncology platforms
Galera Therapeutics is a biopharmaceutical company whose platform aims to protect patients' healthy tissue from the side effects of radiation therapy during cancer treatment. This chart shows the overall sentiment in the oncology platform sector. It helps separate the GRTX momentum from the general "noise" in the biotech sector.
RSI 14 for the overall market
Galera Therapeutics (GRTX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GRTX (Galera Therapeutics)
Galera Therapeutics is a biopharmaceutical company developing drugs designed to protect patients' healthy tissue from the side effects of radiation therapy. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GRTX-Galera-Therapeutics&v=1772669090406 "A chart showing analyst consensus forecasts for the expected stock price. GRTX (Galera Therapeutics)")
The difference between the consensus estimate and the actual stock price GRTX (Galera Therapeutics)
Galera is a "shield" for radiation therapy. The biotech company develops drugs (avasopasem) to protect healthy tissue in patients during radiation treatment. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, reflecting their confidence in this R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GRTX-Galera-Therapeutics&v=1772669090408 "A chart showing the difference between the consensus forecast and the actual stock price. GRTX (Galera Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology platforms
Galera Therapeutics is a biotech company focused on protecting healthy tissue in patients undergoing radiation therapy. This chart displays analysts' overall expectations for the onco-platform sector. It shows whether experts believe the market for "companion" therapies in cancer treatment will grow.
Analysts' consensus forecast for the overall market share price
Galera Therapeutics is a biotech company specializing in drugs that protect patients' healthy tissue from the side effects of radiation therapy for cancer. This chart reflects the overall market "risk appetite." For Galera, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Galera Therapeutics
Galera is a biotech R&D company that failed. Their key product (Avasopasem) was a protective drug designed to protect healthy tissue (the mouth) from radiation therapy. It failed Phase 3. This chart is a summary of their battle for survival. It reflects their (failed) R&D, their (disappearing) cash, and their (desperate) race to keep up.
AKIMA Market Segment Index - Oncology platforms
Galera Therapeutics is an oncology company that doesn't cure cancer but rather combats its side effects. Their drugs are designed to protect patients' healthy tissue from radiation therapy. This is an adjuvant oncology company. This chart compares their composite index to the sector, showing how their protective platform outperforms others.
The AKIM Index for the overall market
Galera Therapeutics is a biopharmaceutical company developing drugs to reduce the side effects of cancer radiation therapy (avasopasem). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which has faced regulatory denials, compares to overall economic trends.
